The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential ...

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

When some of America’s most-influential CEOs were asked recently how much the stock market would need to fall before they ...

During the meeting with Li, he was joined by the leaders of several American businesses, including FedEx Corp. CEO Raj Subramaniam, Boeing Co.'s senior vice president Brendan Nelson, Qualcomm's CEO ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...